Physician profile
Julia Ford
NPI 1962815274
$777.71
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $58.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.01 | 2019 | |
| Genentech, INC. | $119.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $98.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $61.35 | 2019 | |
| Glaxosmithkline, LLC. | $61.24 | 2019 | |
| Amgen INC. | $58.28 | 2019-2020 | |
| Ucb, INC. | $57.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $55.83 | 2019-2020 | |
| Pfizer INC. | $40.81 | 2019 | |
| Celgene Corporation | $22.71 | 2019 | |
| Genentech USA, INC. | $18.06 | 2020 | |
| Janssen Biotech, INC. | $11.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.